Gritgen Therapeutics is focused on advancing gene therapy technologies, particularly through its proprietary platforms. One of the key technologies is the GritPAC® platform, which enhances protein expression significantly, as demonstrated in non-human primate studies and clinical trials. This platform allows for the achievement of microgram-per-liter levels of protein expression in blood, thereby expanding the company's therapeutic pipeline. Additionally, Gritgen has developed a next-generation AAV capsid platform, GritOcul®, aimed at providing long-lasting treatments for ophthalmological diseases. This innovative approach utilizes adeno-associated virus (AAV) vectors, which are known for their safety and ability to integrate into the target cell's genome without causing significant immune reactions.

The company employs a comprehensive process development strategy for both AAV and plasmid production, ensuring high yields and quality control throughout manufacturing. Their facilities, which span 8,600 square meters, are compliant with Good Manufacturing Practices (GMP) and are equipped with advanced production lines for plasmids and AAVs. Gritgen's integrated quality control system adheres to regulatory requirements, focusing on the identification, quantitation, activity, and purity of the products, while also ensuring safety through rigorous testing for sterility and contaminants. This robust framework positions Gritgen Therapeutics as a promising player in the biotech industry, dedicated to innovative research and the development of effective gene therapies.

China

Gritgen Therapeutics (here in after designated as "Gritgen") was founded in China and is a biotechnology company focused on gene therapy. They have launched a commercial GMP facility in China and have opened a good manufacturing practice (GMP) facility in Suzhou Industrial Park. Gritgen provides an important vector foundation for the company to realize gene therapy for hemophilia A. The company has also launched a Phase 1 clinical trial to assess the safety of gene therapy for hemophilia A.

Gritgen Therapeutics

Company Details